Division of Strategic Planning and Evaluation FY2023 List of Projects - Research Program on Emerging and Re-emerging Infectious Diseases
| First Year | Final Year | Principal Investigator | Affiliation | Project Title | |
|---|---|---|---|---|---|
| FY2021 | FY2023 | TAKAHASHI Hitoshi |
National Institute of Infectious Diseases | Chief | Study on cell-based influenza vaccine |
| FY2021 | FY2023 | MURAKAMI Shin |
The University of Tokyo | Associate Professor | Study of preparedness for new MERS-like coronavirus outbreak |
| FY2021 | FY2023 | MIZUKAMI Takuo |
National Institute of Infectious Diseases | Chief | Research and Development of a Hyperimmune Globulin Product against Mother-to-Child Transmission of HTLV-1 |
| FY2021 | FY2023 | SUGAI Motoyuki |
National Institute of Infectious Diseases | Director | Studies on strengthening the AMR surveillance and the comprehensive promotion of countermeasures to AMR |
| FY2021 | FY2023 | OHNISHI Makoto |
National Institute of Infectious Diseases | Guest Research Scientist | Study of Antimicrobial resistance of Neisseria gonorrhoeae and Mycoplasma genitalium infections. |
| FY2021 | FY2023 | KOMATSUZAWA Hitoshi |
Hiroshima University | Professor | Study of the inhibition of colonization of drug-resistant bacteria in the oral cavity and upper respiratory tract |
| FY2021 | FY2023 | MITARAI Satoshi |
Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association | Professor/Head | A comprehensive basic study against difficult factors for tuberculosis control |
| FY2021 | FY2023 | HOSHINO Yoshihiko |
National Institute of Infectious Diseases | Chief | The development of novel treatment strategy regarding mechanism of latency and re-activation of mycobacterial infection using epidemiological observation |
| FY2021 | FY2023 | OKADA Masaji |
National Hospital Organization, Kinki-chuo Chest Medical Center | Visiting Senior Scientist | Study of a therapy (A Novel Therapeutic Vaccine) against tuberculosis and diagnosis for latent tuberculosis infection |
| FY2021 | FY2023 | MIYAZAKI Yoshitsugu |
National Institute of Infectious Diseases | Director | Study of leprosy toward elimination and control |
| FY2021 | FY2023 | IYODA Sunao |
National Institute of Infectious Diseases | Chief | Research for the establishment of surveillance and virulence evaluation methods of diarrheagenic bacterial pathogen derived from severe cases |
| FY2021 | FY2023 | SUZUKI Motoi |
National Institute of Infectious Diseases | Director | Research on surveillance for vaccine-preventable diseases and the evaluation of vaccine effectiveness |
| FY2021 | FY2023 | KASAI Shinji |
National Institute of Infectious Diseases | Director | Studies on the arthropod vectors that transmit infectious diseases |
| FY2021 | FY2023 | ANDO Shuji |
National Institute of Infectious Diseases | Chief | Comprehensive study for tick-borne infectious diseases |
| FY2021 | FY2023 | MAEDA Ken |
National Institute of Infectious Diseases | Director | Comprehensive studies on countermeasure to companion animal-borne diseases |
| FY2021 | FY2023 | KUROSAKI Yohei |
Nagasaki University | Associate Professor | Study of practical biorisk management in the microbiological containment laboratories |
| FY2021 | FY2023 | FUKUHARA Takasuke |
Hokkaido University | Professor | Establishment of novel high-speed reverse genetics system for all RNA viruses |
| FY2021 | FY2023 | OGURA Yoshitoshi |
Kurume University School of Medicine | Professor | Development of new therapeutic and preventive strategy for Clostridioides difficile infection |
| FY2021 | FY2023 | UEMATSU Satoshi |
Osaka City University | Professor | Development of innovative phage therapy based on comprehensive metagenomic analysis |
| FY2021 | FY2023 | UCHIDA Satoshi |
Tokyo Medical and Dental University | Professor | Development of mRNA nano-vaccines possessing double-stranded RNA in mRNA side chains for pandemics |
| FY2021 | FY2023 | NAMKOONG Ho |
Keio University School of Medicine | Associate Professor | Elucidation of pathogenesis of NTM pulmonary disease based on integrated analysis of host and pathogen genomes |
| FY2021 | FY2023 | MISAWA Takashi |
National Institute of Health Sciences | Chief | Study of middle-size drugs for multi-drug resistance bacteria |
| FY2021 | FY2023 | KATOH Hiroshi |
National Institute of Infectious Diseases | Chief | Elucidation of the neurotropic mechanism of mumps virus by identification of receptor glycans and its application to therapy |
| FY2022 | FY2024 | SHIMOJIMA Masayuki |
National institute of Infectious Diseases | Chief | Study on treatment against viral hemorrhagic fevers |
| FY2022 | FY2024 | EBIHARA Hideki |
National Institute of Infectious Diseases | Director | Integrated research for the establishment of a scheme to control emerging tick-borne viral diseases in Japan |
| FY2022 | FY2024 | KAWAOKA Yoshihiro |
The University of Tokyo | Project Professor | Evaluation of the therapeutic effects of novel compounds against highly pathogenic avian influenza viruses |
| FY2022 | FY2024 | ARITA Minetaro |
National Institute of Infectious Diseases | Chief | Integrated study on development of diagnostic, therapeutic, and preventive strategies for emerging and re-emerging enterovirus infections by multidiscipline research |
| FY2022 | FY2024 | MORI Yoshio |
National Institute of Infectious Diseases | Chief | Study of sustainable surveillance contributing to elimination of measles and rubella |
| FY2022 | FY2024 | MATSUOKA Masao |
Kumamoto University | Professor | Establishment of highly accurate prediction method for HTLV-1-associated diseases and development of dendritic cell therapy by ATL cell reprogramming |
| FY2022 | FY2024 | MORIKAWA Kazuya |
University of Tsukuba | Professor | Study of acquisition and stabilization of staphylococcal drug resistance |
| FY2022 | FY2024 | SHIN-YA Kazuo |
National Institute of Advanced Industrial Science and technology | Group Leader | A new strategy to create drugs to overcome multidrug-resistant bacteria using innovative natural compound derivatization technology |
| FY2022 | FY2023 | SHINTANI Yasunori |
National Cerebral and Cardiovascular Center | Director | Therapeutic development targeting drug-resistant Neisseria gonorrhoeae and Pseudomonas aeruginosa |
| FY2022 | FY2024 | IKEDA Haruo |
Next generation Natural Products Chemistry | Research Fellow | Derivatization and development of potent antimycobacterial agents by the next-generation technique |
| FY2022 | FY2024 | MAEDA Ken |
National Institute of Infectious Diseases | Director | Comprehensive studies on countermeasure to zoonoses and establishment of the network |
| FY2022 | FY2024 | ATO Manabu |
National institute of infectious diseases | Director | Study of antitoxins/antivenoms and their replacement by humanized monoclonal antibodies |
| FY2022 | FY2024 | KURODA Makoto |
National Institute of Infectious Diseases | Director | Study of comprehensive pathogen surveillance system based on the epidemiology and genome information |
| FY2022 | FY2024 | SUZUKI Tadaki |
National Institute of Infectious Diseases | Director | Pathological method development for congenital infections and unexplained illness of possible infectious etiology |
| FY2022 | FY2024 | MIZUNO Seiya |
University of Tsukuba | Professor | Development of Fundamental Technology for the Generation of Genetically Humanized Mice as Pathogenic Animal Models for Emerging Viral Diseases |
| FY2022 | FY2024 | MARUYAMA Haruhiko |
University of Miyazaki | Professor | Establishment of medical care network for the adequate treatment of imported tropical diseases and rare parasitic infections in Japan |
| FY2022 | FY2024 | KAWAGUCHI Yasushi |
University of Tokyo | Professor | Establishment of next-generation BAC system and high-speed analysis to accelerate the identification of notable mutant strains |
| FY2022 | FY2024 | KAWASE Takakazu |
Fujita Health University | Associate Professor | Development of universal T cell therapy for Cytomegalovirus (CMV) disease |
| FY2022 | FY2024 | KINOSHITA-Daitoku Ryo | Nagoya University Graduate School of Medicine | Assistant Professor | Development of innovative therapeutic agents for antimicrobial-resistant bacterial infections using the Ω systems |
| FY2022 | FY2024 | YAMAMOTO Mizuki |
University of Tokyo | Senior assistant Professor | Identification of membrane fusion inhibitor for Dengue and Zika virus |
| FY2022 | FY2024 | MATSUNO Keita |
Hokkaido University | Associate Professor | Development of comprehensive bunyavirus detection system for acute febrile illness |
| FY2022 | FY2024 | OHASHI Hirofumi |
National Institute of Infectious Diseases | Researcher | Research and development of the broad-spectrum antiviral compounds through targeting viral infection induced membrane compartment, double membrane vesicle |
| FY2022 | FY2024 | KIDOKORO Minoru |
National Institute of Infectious Diseases | Senior Researcher | Study on the development of a safer and more effective novel mumps vaccine derived from a current Japanese vaccine strain |
| FY2022 | FY2024 | KIMIZUKA Yoshifumi |
National Defense Medical College | Assistant Professor | Study of non-contact and non-invasive mucosal vaccine enhancing technology by near infrared laser |
| FY2022 | FY2024 | TSUJIMURA Yusuke |
National Institute of Infectious Diseases | Senior Research Scientist | Development of new tools for prevention of tuberculosis infection using recombinant BCG vaccine and nasal vaccine inducing mucosal immunity |
| FY2022 | FY2024 | ISHII Koji |
National Institute of Infectious Diseases | Director | Study of the establishment of quality control methods of existing vaccines |
| FY2022 | FY2024 | SUGA Shigeru |
National Hospital Organization Mie National Hospital | Vice Director | Basic, clinical, and epidemiological research that contributes to the verification of the usefulness of existing vaccines and the improvement of future vaccination measures |
| FY2022 | FY2024 | MATSUMOTO Koji |
Showa University School of Medicine | Professor | Study for monitoring the impact of a national HPV vaccination program in Japan (MINT study II) |
| FY2022 | FY2024 | EBIHARA Hideki |
National Institute of Infectious Diseases | Director | Establishment of animal models and evaluation schemes to develop medical countermeasures for viral hemorrhagic fevers |
| FY2022 | FY2024 | SENOH Mitsutoshi | National Institute of Infectious Diseases | Chief | Research for solidifying the infrastructure for the treatment, prevention, and diagnosis for rare bacterial infectious diseases |
| FY2022 | FY2024 | SHIME Nobuaki | Hiroshima University | Professor | Clinical evidence building for medical care support and development of new medical devices for severe COVID-19 patients using revised CRISIS platform |
| FY2022 | FY2024 | ABE Takaaki | Tohoku University | Professor | Study of mitochondria-based antiviral drugs for emerging and re-emerging infectious diseases |
| FY2023 | FY2025 | LIM Chang-Kweng | National Institute of Infectious Diseases | Chief | Research on prevention, treatment, diagnosis, and control for arbovirus infectious diseases |
| FY2023 | FY2025 | IWASAKI Masaharu | Osaka University | Specially Appointed Associate Professor | Study to establish the molecular basis for the development of novel prophylactics and therapeutics for hemorrhagic fever-causing arenavirus infections |
| FY2023 | FY2025 | OKAMOTO Toru | Juntendo University | Professor | Exploration of molecular basis investigation for arthropod-borne flavivirus infection using novel imaging technologies |
| FY2023 | FY2025 | KAWAOKA Yoshihiro | The University of Tokyo | Project Professor | Development of next-generation Ebola virus vaccines |
| FY2023 | FY2025 | MAEDA Ken | National Institute of Infectious Diseases | Director | Comprehensive studies on infection with orthopoxviruses including Mpox virus |
| FY2023 | FY2025 | SHIRATO Kazuya | National Institute of Infectious Diseases | Chief | Studies on construction of surveillance system, epidemiology, pathogenesis, and aggravating factors for respiratory syncytial virus infections |
| FY2023 | FY2025 | WATANABE Shinji | National Institute of Infectious Diseases | Chief | Establishment of a prediction method for seasonal influenza viruses based on their structure, antigenicity, and genetic information and its use for vaccine candidate selection |
| FY2023 | FY2025 | IZUMIYA Hidemasa | National Institute of Infectious Diseases | Chief | Understanding of the current situation of AMR using genomic surveillance and the development of effective tools, based on ASPIRE |
| FY2023 | FY2025 | SUGAI Motoyuki | National Institute of Infectious Diseases | Director | Advanced One Health Tricycle Project developed in cooperation with Asian countries |
| FY2023 | FY2025 | SUZUKI Masato | National Institute of Infectious Diseases | Senior Researcher | Analysis of dynamics of antimicrobial resistance genes circulating in clinical and environmental settings using innovative methods |
| FY2023 | FY2025 | MATSUNAGA Nobuaki | National Center for Global Health and Medicine | Director | Study of monitoring of antimicrobial resistant bacteria and residual antimicrobials in healthcare associate facilities wastewater and development of rapid, high-volume analysis methods |
| FY2023 | FY2025 | KAGEYAMA Tsutomu | National Institute of Infectious Diseases | Director | Study on a diarrhea virus for infectious disease control based on molecular epidemiology |
| FY2023 | FY2025 | KIYONO Hiroshi | Chiba University | Distinguished Professor | Development of innovative mucosal vaccines, antibody drugs, rapid diagnostics, and in vitro evaluation systems against diarrhea viruses based on epidemiological studies and changes in trend |
| FY2023 | FY2025 | SOMEYA Yuichi | National Institute of Infectious Diseases | Chief | Cell biological and structural studies of diarrheal viruses for facilitating the development of antiviral drugs and vaccines |
| FY2023 | FY2025 | TACHIKAWA Ai | National Institute of Infectious Diseases | Chief | Study on the development of iPS-derived anti-CADM1 CAR-T cell therapy for HTLV-1 cure |
| FY2023 | FY2025 | MIURA Kiyonori | Nagasaki University | Professor | Study of trends in HTLV-1 horizontal infection and establishment of testing method and system |
| FY2023 | FY2025 | YAMAGISHI Makoto | The University of Tokyo | Associate Professor | Comprehensive study on elucidation of pathogenesis of HTLV-1 infection based on genome information and development of risk prediction algorithm |
| FY2023 | FY2025 | ATO Manabu | National Institute of Infectious Diseases | Director | Study of surveillance, pathogenesis, drug resistance mechanisms based on genome and clinical information of non-tuberculous Mycobacterial diseases contributing to novel diagnostic methods and development of new therapeutic agents |
| FY2023 | FY2025 | KATO Seiya | Research Institute of Tuberculosis, Japan Anti- Tuberculosis Association |
Director | Study on tuberculosis control in low incidence by strengthening collaboration and innovative technology |
| FY2023 | FY2025 | TSUYUGUCHI Kazunari | National Hospital Organization Kinki-Chuo Chest Medical Center | Director | Study of innovative treatment strategy and ideal medical system for intractable and multidrug-resistant tuberculosis |
| FY2023 | FY2025 | AKEDA Yukihiro | National Institute of Infectious Diseases | Director | Understanding of Syphilis using genomic epidemiological analysis and pathogen detection |
| FY2023 | FY2025 | YANAGIHARA Itaru | Osaka Women's and Children's Hospital | Director | Applied research on the control of Ureaplasma spp. infection associated with preterm birth |
| FY2023 | FY2025 | RIMBARA Emiko | National Institute of Infectious Diseases | Chief | Study of non-Helicobacter pylori Helicobacter species infection |
| FY2023 | FY2025 | YOSHITSUGU Miyazaki | National Institute of Infectious Diseases | Director | Study of development of novel diagnositics and treatments against invasive yeastinfections |
| FY2023 | FY2025 | NOZAKI Tomoyoshi | The University of Tokyo | Professor | Basic and applied studies on the prevention and chemotherapy against parasitic diseases endemic in Japan |
| FY2023 | FY2025 | HISAEDA Hajime | National Institute of Infectious Diseases | Director | Research for strengthening countermeasures for domestic and imported parasitic diseases |
| FY2023 | FY2025 | YAMAMOTO Masahiro | Osaka University | Professor | Comprehensive research and development for understanding the pathogenesis and the infection status, and controlling of human apicomplexan parasitic diseases caused by Toxoplasma and Cryptosporidium in Japan |
| FY2023 | FY2025 | MATANO Tetsuro | National Institute of Infectious Diseases | Deputy-Director General | Study for the establishment of an advanced collaboration and communication network among research institutes on infectious diseases in Asian countries |
| FY2023 | FY2025 | SUZUKI Tadaki | National Institute of Infectious Diseases | Director | Development of Fundamental Technology for Controlling Viral shedding of Respiratory Virus Infections by Mucosal Antibodies |
| FY2023 | FY2025 | NISHIURA Hiroshi | Kyoto University | Professor | Implementation of mathematical modelling for infectious disease control and joint studies with clinical infectious diseases |
| FY2023 | FY2025 | UWAMINO Yoshifumi | Keio University | Assistant Professor | Study of Development of Point-of-care Testing-type tools for Grasping and Predicting Trends in Immunity against Novel Influenza Virus Infections |
| FY2023 | FY2025 | MATSUMOTO Yusuke | Kagoshima University | Associate Professor | Development of a technology generating pan-paramyxovirus live-vaccine and its application for a novel vaccine vector |
| FY2023 | FY2025 | KOBAYASHI Nobuhide | Tokyo Metropolitan Institute of Medical Science | Emeritus Investigator | Study of non-proliferative attenuated vaccinia virus against orthopoxvirus infection |
| FY2023 | FY2023 | KOHARA Michinori | Kanazawa University | Assistant professor | Development of prevention and treatment of infant botulism using the colonization resistance against foreign spores by commensal microbiota |
| FY2023 | FY2023 | MORIOKA Shinichiro | National Center for Global Health and Medicine | Chief | Research and development of treatment and prevention systems for mpox in Japan |
| FY2023 | FY2023 | UJIIE Mugen | National Center for Global Health and Medicine | Chief | Clinical study of LC16m8 for efficacy and safety against monkeypox |
| FY2023 | FY2023 | SHINOHARA Naoki | Japan Biotechno Pharma Co., Ltd | Founder & CEO | Development of therapeutic agents for infections caused by orthopox viruses including monkeypox |
| FY2023 | FY2023 | WATANABE Rikiya | RIKEN | Chief Scientist | Development of a novel amplification-free nucleic acid test for rapid diagnosis of orthopoxvirus infection |
| FY2023 | FY2023 | TAKAYAMA Kazuo | Kyoto University | Junior Associate Professor | Characterization of Mpox virus (2022 outbreak strain) using human in vitro higher-order evaluation system |
| FY2023 | FY2023 | KAKU Natsuko | Osaka Metropolitan University | Specially appointed lecturer | Understanding immunological protectability of smallpox-vaccinated people against infection with monkeypox virus |
| FY2023 | FY2023 | NAKAMURA Kensuke | Yokohama City University | Associate Professor | Drug repositioning of donepezil for the treatment of COVID-19 sequelae. - Investigator Initiated Clinical Trial - |
| FY2023 | FY2023 | TERAI Hideki | Keio University | Assistant Professor | Creation of novel treatment strategies based on findings from the large long COVID cohort study |
| FY2023 | FY2023 | OKADA Satoshi | Hiroshima University | Professor | Comprehensive approach-based characterization of pathophysiology and clinical manifestation of Multisystem Inflammatory Syndrome in Children |
| FY2023 | FY2023 | KONDO Kazuhiro | The Jikei University School of Medicine | Professor | Generation of model mice for Post COVID-19 Condition due to herpesvirus reactivation, elucidation of onset mechanism, and development of diagnostic biomarkers |
| FY2023 | FY2023 | FUKUHARA Takasuke | Hokkaido University | Professor | Establishment of in vivo model that can evaluate post-infection symptoms of SARSCoV-2 and elucidation of the mechanism of pathogenesis |
| FY2023 | FY2023 | UEHARA Takashi | Okayama University | Professor | Effects of proprietary compound on epigenomic changes and long COVID mediated by excess NO production evoked by coronavirus infection |
| FY2023 | FY2023 | MIYAKAWA Kei | National Institute of Infectious Diseases | Chief | Development of preventive strategies for Long COVID using mini-gut organoids |
| FY2023 | FY2023 | SUZUKI Tadaki | National Institute of Infectious Diseases | Director | Study on Clinical, Virological, and Immunological Characteristics of Long-Term SARS-CoV-2 Shedders |
| FY2023 | FY2023 | FUKUNAGA Koichi | Keio University | Professor | Elucidation of novel pathogenesis and creation of therapeutic strategy of COVID-19 by multi-omics integrative analysis |
| FY2023 | FY2023 | SATO Kei | The University of Tokyo | Professor | Development of a research consortium to overcome COVID-19 |
| FY2023 | FY2023 | KITAJIMA Masaaki | Hokkaido University | Associate Professor | Establishment of a surveillance system for epidemics and imported infectious diseases based on comprehensive molecular epidemiological analysis of pathogens in wastewater |
| FY2023 | FY2023 | SUZUKI Yuta | Eisai Co., Ltd. | Group Leader | Establishment of a technology platform for the production of in vivo protein drugs and domestic manufacturing in an emergency |
| FY2023 | FY2023 | MATSUOKA Ken | Osaka University | Associate Professor | Development of novel therapeutic agents for fulminant myocarditis associated with severe viral infection |
| FY2023 | FY2023 | ARIMORI Takao | Osaka University | Associate Professor | Development of high affinity DPP4 decoys to treat MERS |
| FY2023 | FY2023 | HIROAKI Hidekazu | Nagoya University | Professor | Development of drugs targeting SARS-CoV-2 E protein-mediated viral particle formation |
| FY2023 | FY2023 | SUGIURA Wataru | National Center for Global Health and Medicine | Director |
Research on the development of fundamental systems and procedures for conducting clinical research on drug development in response to emerging and reemerging
infectious disease epidemics
|
| FY2023 | FY2023 | WATASHI Koichi | National Institute of Infectious Diseases | Director | Establishment of infrastructure of experimental infection technologies for facilitating drug development against priority infectious diseases |
| FY2023 | FY2023 | TAKAZONO Takahiro | Nagasaki University | Associate Professor | Development of new treatments for drug-resistant filamentous fungal infections using immune-effector cells |
| FY2023 | FY2023 | NISHINO Kunihiko | Osaka University | Professor | Development of MexB and MexY dual inhibitor against muliti-drug resistant Pseudomonas aeruginosa infectious diseases |
| FY2023 | FY2023 | KIGA Kotaro | National Institute of Infectious Diseases | Group leader | Development of novel phage-based antimicrobials against bacteria with solid defense systems |
| FY2023 | FY2023 | TAKAHASHI Yoshimasa | National Institute of Infectious Diseases | Director | Immune profiling study for counteracting COVID-19 |
| FY2023 | FY2023 | IRIE Takashi | Hiroshima University | Associate Professor | Establishment of a rapid recombinant virus production system for mononegaviruses and its application development |
| FY2023 | FY2023 | YAMADA Hiroshi | Okayama University | Associate Professor | Study of the malaria parasite division machinery for novel antimalarial drug targets |
| FY2023 | FY2023 | OGAWA Haruo | Kyoto University | Associate Professor | Study of multidrug transporter cdr1p from Candida auris |
| FY2023 | FY2023 | ASAKURA Takanori | Kitasato University | Junior Associate Professor | Creation of airway region-specific epithelial cell-based molecular system to prepare for infections causing new severe acute respiratory syndromes |
| FY2023 | FY2023 | NAOYOSHI Nagata | Tokyo Medical University | Associate Professor | Study of the antibiotic-resistant bacteria pathophysiology and control from gut ecosystem dynamics |
| FY2023 | FY2023 | NAITO Mitsuru | The University of Tokyo | Assistant Professor | Development of mRNA vaccine for inducing mucosal immunity |
| FY2023 | FY2023 | NAKANO Satoshi | National Institute of Infectious Diseases | Senior Researcher | National surveillance study of Streptococcus agalactiae colonization and infection in pregnant women, newborns, infants and elders |
| FY2023 | FY2023 | SUMAZAKI Ryo | National Center for Global Health and Medicine | Researcher | Exploring the epidemiology, pathogen, pathophysiology, and developing the treatment for pediatric acute hepatitis of unknown aetiology |
| FY2023 | FY2023 | TAKEMAE Nobuhiro | National Institute of Infectious | Diseases Chief | Research on the development of highly sensitive and rapid methods for comprehensive analysis and detection of respiratory viral genes to the enhancement of infectious disease control |
| FY2023 | FY2023 | WATANABE Rikiya | RIKEN | Chief Scientist | Multicenter clinical research of amplification-free rapid viral genome detection technology for prevention of respiratory infections |
| FY2023 | FY2023 | MIYAZAKI Taiga | University of Miyazaki | Professor | Epidemiological studies and research and development of innovative diagnostic and therapeutic strategies for mold infections |
05/31/23
Last updated 08/10/23